Absci Accelerates AI-Driven Drug Discovery through Oracle and AMD Collaboration

Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration - Absci (NASDAQ:ABSI)

Absci Inc. ABSI on Thursday collaborated with Oracle Corporation's ORCL Oracle Cloud Infrastructure (OCI) and AMD Inc. AMD to accelerate generative AI-driven drug discovery. Absci's generative AI Drug Creation Platform leverages OCI's AI infrastructure and AMD's latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles. Also Read: Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Scaling AI-Driven Drug Discovery Fifth-generation AMD EPYC processors and RDMA cluster networking power OCI's bare metal instances. They provide Absci with the low-latency networking and throughput required for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody-antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 µs, and benefit from terabytes-per-second throughput for checkpointing and data streaming. "Absci's generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for," said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. "By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we're providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design." Price Action: ABSI stock is up 10.50% at $2.63 at the last check on Thursday. Read Next: Ecovyst Streamlines Focus As Technip Energies Snaps Up Catalysts Business Image: Shutterstock ABSIAbsci Corp$2.7515.3%Stock Score Locked: Edge Members Only Benzinga Rankings give you vital metrics on any stock - anytime. Unlock RankingsEdge RankingsMomentum10.15Price TrendShortMediumLongOverviewAMDAdvanced Micro Devices Inc$155.99-2.23%ORCLOracle Corp$318.11-3.11%Market News and Data brought to you by Benzinga APIs

Absci accelerates AI-driven drug discovery with Oracle and AMD

Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.